On Jun. 9, 2020, Immunic announced receipt of regulatory allowance from the FDA to initiate its phase 2, CALVID-1 clinical trial of IMU-838, the company’s selective oral DHODH inhibitor, in coronavirus disease 2019 (COVID-19) at centers in the U.S.